Core Insights - Dividend Kings are companies that have increased their dividend payments for at least 50 consecutive years, providing a reliable long-term investment strategy [1] - Several Dividend Kings, including Coca-Cola, Johnson & Johnson, and Consolidated Edison, have achieved over 100% total return in the past decade, suggesting a potential for doubling investments in the next 10 years through a buy-and-hold strategy [1] Group 1: Coca-Cola - Coca-Cola increased its dividend payment by 5.2% this year, marking its 63rd consecutive year of dividend growth [3] - The company has delivered a total return of approximately 125% over the past decade, equating to an annualized return of 8.4% [3][4] - Coca-Cola aims for organic revenue growth of 4% to 6% per year and high-single-digit earnings-per-share growth, supported by a strong balance sheet and significant investments in product innovation and marketing [4][5] Group 2: Johnson & Johnson - Johnson & Johnson raised its dividend payment by 4.8% this year, also extending its dividend growth streak to 63 years [6] - The company has achieved a total return exceeding 165% over the past decade, with an annualized return of 10.3% [6] - Johnson & Johnson holds a AAA bond rating, indicating a strong financial profile, and consistently produces resilient earnings [8]

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. “We are ...

Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences’ scientific platform, c ...

--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a biotech company focused on advancing cancer treatments, today announced it is expanding its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial with LIXTE’s proprietary compound, LB-100 ...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package highlights long-term safety profile, broad-spectrum clinical activity, and favorable adherence observed to date for once daily brilaroxazine over up to one year Initiation of RECOVER-2 registrational trial planned in H1 2026, subject to sufficient financing CUPERTI ...

Core Insights - Ipsen has secured a licensing deal for a Chinese-developed antibody drug conjugate (ADC) that could exceed $1 billion, highlighting the growing significance of ADCs in the oncology sector in 2025 [1][2]. Company Summary - Ipsen has signed a licensing agreement with Simcere Zaiming for the ADC asset SIM0613, which is set to begin clinical development in 2026. The deal grants Ipsen global rights for the cancer treatment outside of Greater China, with potential payments to Simcere Zaiming reaching $1.06 billion [2]. - Ipsen will manage manufacturing rights and oversee Phase I preparation activities, including regulatory submissions. The therapy has shown promising results in preclinical models, with plans for a Phase I trial in cancer patients anticipated in the second half of 2026 [3]. - SIM0613 targets the LRRC15 protein, which is highly expressed in various tumor types and cancer-associated fibroblasts, while exhibiting limited expression in normal cells, allowing for a targeted approach in killing cancer cells [4]. - Ipsen has been actively expanding its oncology portfolio, adding over 20 early-stage programs since 2020, and aims to position itself as a leader in the oncology market [5]. Industry Summary - The ADC market is experiencing rapid growth, with projected revenues expected to exceed $45 billion by 2030, indicating a strong investment trend among pharmaceutical companies [6]. - Major pharmaceutical companies, including Boehringer Ingelheim and Roche, have made significant investments in ADC technologies this year, reflecting the competitive landscape and the increasing importance of ADCs in cancer treatment [7].

Group 1: Novo Nordisk and Obesity Treatment - Novo Nordisk received FDA approval for the first-ever obesity treatment pill, set to launch early next year at a starting dose of 1.5 milligrams for $149 per month [7] - The approval is seen as a landmark decision that could expand access for patients suffering from obesity [1] - Following the news, shares of Novo Nordisk surged by 7%, while competitor Eli Lilly's shares fell by over 1% as it attempts to launch its own obesity pill [7] Group 2: Paramount and Warner Bros. Discovery - Paramount Skydance secured the backing of billionaire Larry Ellison in its bid for Warner Bros. Discovery, addressing concerns about financing from WBD's board [2][3] - WBD investors face a decision to either accept a sale to Netflix or tender their shares to Paramount, with potential implications for shareholder value [3] Group 3: Alphabet and Data Center Acquisition - Alphabet announced its acquisition of data center company Intersect for $4.75 billion in cash, which includes assuming its debt, aimed at enhancing data center capacity [5] Group 4: Janus Henderson Acquisition - Trian Fund Management and General Catalyst are set to acquire asset manager Janus Henderson for $49 per share, valuing the company at approximately $7.4 billion, with shares rising over 3% following the announcement [6] Group 5: Electric Vehicle Market Trends - The initial excitement around electric vehicles (EVs) has diminished, with legacy automakers now prioritizing traditional trucks and SUVs over EVs due to unmet demand expectations [9][10] Group 6: Instacart Pricing Strategy - Instacart announced the end of its AI-driven pricing tests after consumer concerns about price discrepancies for identical items, indicating a shift in its pricing strategy [11][12]

Novo Nordisk has received FDA approval to sell an oral version of Wegovy in the US. This could boost its efforts to regain ground in the weight-loss drug market. Here's what to know. https://t.co/cNwH6MWXnR ...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ARO-INHBE and ARO-ALK7 Interim Clinical Data – January 6, 2026 Type: Company KOL Webinar Date/Time: January 6, 2026, 11:30 a.m. EST J.P. Morgan 2026 Healthcare Conference – January 12-15, 2026 Type: Corporate Presentation Date/Time: January 12, 2026, 10:30 a.m. EST Presentation materials and webcast links, i. ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Spotify.Getty Images Good morning! Here is the latest in trending:First-mover advantage: Novo Nordisk (NVO) is on the rise after the FDA approved its Wegovy pill, the first oral GLP-1 therapy for obesity.Eye on China: Nvidia (NVDA) is reportedly aiming to start shipping its H200 GPUs to China by mid-February, subject to government approval.Another setback: The U.S. government suspended leases ...